CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 132 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2021. The put-call ratio across all filers is 1.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $10,784,000 | +5.5% | 400,000 | +33.3% | 5.62% | +153.4% |
Q1 2022 | $10,218,000 | -24.4% | 300,000 | -14.3% | 2.22% | -54.3% |
Q4 2021 | $13,524,000 | -1.8% | 350,000 | +37.3% | 4.85% | +20.4% |
Q3 2021 | $13,767,000 | +44.5% | 255,000 | -10.5% | 4.03% | +53.7% |
Q2 2021 | $9,530,000 | +32.2% | 285,000 | -18.6% | 2.62% | +54.7% |
Q1 2021 | $7,210,000 | – | 350,000 | – | 1.69% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |